Evidence map›Paper›PMID 32610123›Full record

ArticleCell reports2020

T Cell-Intrinsic IRF5 Regulates T Cell Signaling, Migration, and Differentiation and Promotes Intestinal Inflammation.

Jie Yan, Surya P Pandey, Betsy J Barnes, Jerrold R Turner, Clara Abraham

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 46 citations in OpenAlex.

  1. The role of IRF5 as an immune regulator.Biochemical Society transactions · 2026
    Review
  2. Article
  3. Article
  4. TOPK Suppresses the CD8Cancer communications (London, England) · 2026
    Article
  5. Reduced Methylation of IRF5 Gene as a Biomarker for Gestational Diabetes Mellitus.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. TIGIT deficiency promotes autoreactive CD4Nature communications · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jie YanDepartment of Internal Medicine, Yale University, New Haven, CT, USA.
Surya P PandeyDepartment of Internal Medicine, Yale University, New Haven, CT, USA.
Betsy J BarnesCenter for Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, USA.
Jerrold R TurnerDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Clara AbrahamDepartment of Internal Medicine, Yale University, New Haven, CT, USA. Electronic address: clara.abraham@yale.edu.
Yale University · USFeinstein Institute for Medical Research · USHarvard University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
ZO-1-MEDIATED PROTEIN INTERACTIONS: REGULATORS AND INTEGRATORS OF DIVERSE EPITHELIAL FUNCTIONS IN HEALTH AND DISEASER01DK061931 · NIDDK · UNIVERSITY OF CHICAGO · PI JERROLD R. TURNER · 2001 to 2026
$15.0M
Therapeutic targeting of protein interactions to reverse MLCK1-mediated intestinal barrier loss and ameliorate disease.R01DK068271 · NIDDK · UNIVERSITY OF CHICAGO · PI JERROLD R. TURNER · 2005 to 2026
$11.3M
Functional outcomes of inflammatory bowel disease associated variantsR01DK099097 · NIDDK · YALE UNIVERSITY · PI CLARA ABRAHAM · 2013 to 2026
$7.0M
Mechanisms Regulating Innate Immune ResponsesR01AI120369 · NIAID · YALE UNIVERSITY · PI ABRAHAM, CLARA · 2016 to 2020
$2.0M
Identification of a new factor, interferon regulatory factor 5, that controls spontaneous mammary tumorigenesisR21CA195256 · NCI · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI BARNES, BETSY J · 2015 to 2016
$391k
NCATS NIH HHS UL1 TR001863NCI NIH HHS R21 CA195256NIAID NIH HHS R01 AI120369NIDDK NIH HHS P30 DK034989NIDDK NIH HHS R01 DK061931NIDDK NIH HHS R01 DK068271NIDDK NIH HHS R01 DK099097
6 · The paper itself

Abstract

IRF5 polymorphisms are associated with multiple immune-mediated diseases, including ulcerative colitis. IRF5 contributions are attributed to its role in myeloid lineages. How T cell-intrinsic IRF5 contributes to inflammatory outcomes is not well understood. We identify a previously undefined key role for T cell-intrinsic IRF5. In mice, IRF5 in CD4

Indexed as

Cell DifferentiationCell MovementSignal TransductionAnimalsCD4-Positive T-LymphocytesColitisCytokinesGenetic Predisposition to DiseaseHumansInflammationInterferon Regulatory FactorsIntestinesLymph NodesMice, Inbred BALB CReceptors, Antigen, T-CellReceptors, ChemokineCytokinesInterferon Regulatory FactorsIRF5 protein, humanIrf5 protein, mouseReceptors, Antigen, T-CellReceptors, Chemokinecolitiscytokinesgeneticsinflammatory bowel diseaseintestineIRF5T cellsT cell trafficking

Identifiers

PMID32610123
PMCPMC7409536
OpenAlexW3039979076

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.